Debiopharm
Alisporivir (Debio 025) is a cyclosporine-derived cyclophilin inhibitor with historical clinical development. A 2021 trial does not establish current active status.
SwitzerlandFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
471 matching companies
XtalPi
PepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.
ChinaFull profile →
HitGen
The company's interim report describes peptidomimetic macrocycle discovery, optimization, and oral applications. DEL and platform capabilities do not establish human oral evidence for proprietary candidates.
ChinaFull profile →
IRBM
Provides optimization of macrocyclic peptides derived from mRNA / phage display. Its website reports involvement in developing Merck's oral PCSK9 peptide MK-0616.
Curve Therapeutics
Microcycle® functionally screens compact macrocycles in live cells and develops macrocycle-derived drugs. This review did not confirm a named oral cyclic peptide candidate.
United KingdomFull profile →
Orbit Discovery
Its peptide screening platform covers linear, cyclic, and helical structures, so it is included as an adjacent discovery capability. It is not automatically classified as a validated oral cyclic peptide drug developer.
United KingdomFull profile →
Triastek
T25 is an oral octreotide acetate tablet. MED&SSE produces its shell and drug-containing core; FDA IND clearance was disclosed in 2026.
ChinaFull profile →
Henlius
Original company materials confirm cyclic peptides as a development modality. This review did not find a primary announcement sufficient to verify a specific oral candidate and its current stage.
ChinaFull profile →
Sunshine Guojian
An investor record describes program 629 as an oral IL-23 cyclic peptide with PK suggesting once-weekly potential. Human results and the latest stage were not confirmed in this review.
ChinaFull profile →
Sciwind Biosciences
The OralVantage™ oral peptide platform combines molecular stabilization and formulation strategies. It is included as a noncyclic peptide platform reference; validated oral cyclic peptides are not assumed.
ChinaFull profile →
Oralpeptime Biopharma
Founded in 2026, this early-stage oral long-acting peptide company describes molecular design, microbial expression, and OMV packaging / delivery. Cyclic peptide identity and human evidence require verification.
ChinaFull profile →
Bicycle Therapeutics
An important adjacent company in bicyclic peptide screening and conjugation. Its disclosed nonoral clinical pipeline is not evidence of oral cyclic peptide success.
United Kingdom / United StatesFull profile →
Hepion → Panetta Partners
Rencofilstat (CRV431) has oral clinical studies in MASH. Hepion transferred related assets to Panetta in 2025; the record preserves the historical development and change in rights.
United States / 权利承接方地域待核实Full profile →
Sublimity Therapeutics / Sigmoid heritage
ST-0529 is an oral cyclosporine formulation for UC with historical Phase 2 registration. The Romanian record reviewed is marked prematurely ended. Current ownership and company status require verification.
Sorriso Pharmaceuticals
SOR102 is a locally acting oral TNF / IL-23 bispecific single-domain antibody with a primary Phase 1 study. It is included as a noncyclic oral biologic reference.
United StatesFull profile →
Dr. Falk Pharma
The ST-0529 oral cyclosporine Phase 2 registry lists the company as a study supporter. That regional record ended prematurely; current development rights or collaboration budgets are not inferred.
GermanyFull profile →
Merck / MSD
LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.
United StatesFull profile →
Bachem
Provides process development, analytical services, and GMP clinical manufacturing for cyclic peptides, stapled peptides, and peptidomimetics. Classified as a manufacturing service provider; client drugs are not treated as proprietary pipelines.
Switzerland / United StatesFull profile →
WuXi AppTec / WuXi TIDES
The website describes a client case for a non-GLP-1 oral cyclic peptide, from library synthesis and lead optimization through GMP preparation. Only service capability is recorded; the unnamed client is neither identified nor guessed.
China / United StatesFull profile →
Nurix Therapeutics
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
United StatesFull profile →
Biosynth / Pepscan
CLIPS™ supports monocyclic, bicyclic, and tricyclic constrained peptides, screening, and optimization. Recorded at the integrated-group level; oral suitability requires program-level validation.
Switzerland / Netherlands / United StatesFull profile →
AmbioPharm
The company describes constrained peptide chemistry involving disulfides, lactam bridges, stapling, and other cyclization approaches. This review did not confirm a proprietary oral cyclic peptide candidate.
United States / ChinaFull profile →
Menten AI
MAUD 1.0 combines generative AI, physics-based modeling, and quantum simulations to design cyclic peptides. The company explicitly optimizes oral bioavailability and cell permeability and works with pharmaceutical partners on discovery.
United StatesFull profile →
Processa Pharmaceuticals
An October 2026 research collaboration and exclusive option agreement with Generian advances an oral macrocyclic peptide FcRn antagonist. This research-stage program is separate from Processa’s Phase 2 small-molecule BTK inhibitor VT-7208.
United StatesFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.